Christina Fotopoulou’s research while affiliated with Imperial College London and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (388)


Advanced epithelial ovarian cancer in the older patient: a retrospective cohort study of six UK Gynaecological Cancer centers
  • Preprint

April 2025

·

10 Reads

·

·

·

[...]

·

Objective We aimed to analyze management and survival outcomes of older people (≥75 years) with stage II+ epithelial ovarian cancer (EOC) across six gynaecological cancer centers in the United Kingdom. Methods Retrospective cohort study performed using the IMPRESS project dataset. Clinical information for patients diagnosed with EOC from six sites of varying size and population demographics, was collated between 1/1/2018 and 31/12/2019. We compared treatment of patients aged ≥75 years with those <75, within and between centers, using multi-variate analysis, to understand effects on outcomes. Results After exclusions, we assessed 721 people for overall survival (OS) and 702 for progression-free survival (PFS). The ≥75s had poorer performance status, more comorbidities and were less likely to receive combination treatment with surgery and chemotherapy (in either order) (overall = 392/721 (54.4%) overall; <75 cohort = 320/495 (64.6%); ≥75 cohort = 72/226 (31.9%). Treatment proportions varied between sites, with some having no active treatment rates of nearly 50% for ≥75s. Those ≥75 years had twice the relative risk of death compared to those <75 (Relative Risk (RR) = 1.98, 95% confidence intervals (CI) 1.63 to 2.39, P<0.001). Adjustment for confounders individually caused only a relatively modest reduction in magnitude and strength of association. Adjustment for treatment led to this association essentially disappearing (RR = 1.10, 95% CI 0.88 to 1.38; 99% reduction in Chi2), though with significant variation in association between age and OS between treatment groups (p-heterogeneity: 0.0004). Conclusion Older women may do as well as younger women in terms of survival, if treated similarly, although this varies depending on treatment groups. Treatments varied between and within sites, with some sites treating older women more differently than others. Some differences may be appropriate, but significant differences in rates of no active treatment between sites suggests that not all variation may be appropriate.




Location of cerclage placement.
Characteristics of respondents.
Trachelectomy and Cerclage Placement as Fertility-Sparing Surgery for Cervical Cancer—An Expert Survey
  • Article
  • Full-text available

February 2025

·

16 Reads

Background/Objectives: Fertility-sparing surgery (FSS) is a standard practice for managing early stage cervical cancer, yet significant variation exists in clinical approaches worldwide. Our objective was to ascertain current practices and preferences for cerclage use among expert centers globally regarding FSS in patients with early stage cervical cancer. Methods: We conducted a cross-sectional survey from May to July 2023 involving expert centers identified through their scientific contributions and participation in international workgroups and conferences.. The survey, comprising 27 questions, evaluated existing practices in FSS. Results: Out of the centers surveyed, 21 (36.2%) gynecologic oncologists responded. For tumors <2 cm, 86% of centers preferred radical trachelectomy, primarily via the vaginal approach, while 13.6% favored a simple trachelectomy. Three experts preferred simple trachelectomy (13.6%). For tumors >2 cm, 47.6% utilized neoadjuvant chemotherapy before trachelectomy. Others did not offer FSS or performed an abdominal radical trachelectomy. Over time, there has been a shift towards less radical surgeries for tumors <2 cm and increased use of neoadjuvant chemotherapy for larger tumors. Some abandoned the minimally invasive surgical approach. Nearly all experts (90.5%) placed a cerclage immediately following trachelectomy. Conclusions: The majority of experts opt for radical trachelectomy in early stage cervical cancer, with immediate cerclage placement being a common practice. However, considerable international variations highlight the urgent need for standardized guidelines and further research to optimize treatment strategies, balancing oncological safety with fertility outcomes.

Download







Citations (35)


... Studies have demonstrated that the apparent diffusion coefficient from preoperative magnetic resonance imaging correlates more strongly with the updated FIGO 2023 staging, offering a potential tool for enhanced preoperative assessment. 25 However, the increased complexity and detailed stratification of the new system also pose challenges for clinicians, 22 highlighting the need for further research to address these issues. ...

Reference:

Improved practical value of the FIGO 2023 staging system in evaluating prognosis of early stages endometrial carcinoma
FIGO 2023 staging for endometrial cancer, When, if it is not now?
  • Citing Article
  • November 2024

European Journal of Cancer

... A previous guidelines suggested that PARPi maintenance therapy significantly prolongs PFS in patients with advanced OC 32 . However, the extension of OS was reported to be unrelated to PARPi maintenance therapy 33 , which contradicts our findings. Given the frequent side effects and variability in the duration of maintenance therapy, whether PARPi maintenance therapy can effectively improve the prognosis of OC patients requires further validation in multicenter, large-sample real-world setting 34 . ...

Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis
  • Citing Article
  • October 2023

Gynecologic Oncology

... Current guidelines for EOC recommend a combination of chemotherapy and cytoreductive surgery for advanced disease (FIGO stages III and IV). 8 Cytoreduction to leave no macroscopic residual disease (NMRD), is associated with both increased overall (OS) and progression-free survival (PFS). 9 Standard of care may consist of primary cytoreductive surgery (PCRS), followed by platinum-based chemotherapy, or neoadjuvant chemotherapy (NACT) with interval cytoreductive surgery (ICRS), which has been shown to be non-inferior. ...

British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024

European Journal of Obstetrics & Gynecology and Reproductive Biology

... The emergence of ICIs is rapidly changing this grim scenario. Recent meta-analyses [25][26][27][28] have indicated that PD-1/PD-L1 inhibitors outperform conventional regimes in improving overall response rate, PFS, and OS in advanced or recurrent EC patients. However, the quantitative assessment of combination therapies and the comparative evaluation of different treatment regimens remain uncertain. ...

Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis
  • Citing Article
  • May 2024

Gynecologic Oncology

... It is also possible that sex-related differences in Frontiers in Physiology 07 frontiersin.org lower extremity lymphedema may be related to the high rates of lymphedema resulting from relatively common cancers (e.g., cervical, and vulvar) that exclusively affect women (Dessources et al., 2020;Haidopoulos et al., 2024). Sex disparity in lymphedema resulting from filarial infection is more pronounced, with most studies showing significantly increased (and treatment-resistant) filarial antigen prevalence and higher rates and severity of the disease among male patients (Fimbo et al., 2020;Lau et al., 2014). ...

Lower Limb Lymphedema Awareness among Gynecological Cancer Patients: An International Survey Supported by the European Network of Gynecological Cancer Advocacy Groups (ENGAGe) Group

... With the development and application of genome-wide technologies, molecular analysis is currently being used in the diagnosis, treatment, and prognosis of EC. In the latest revised FIGO staging system, the TCGA molecular classification has been integrated to redefine EC. 25,26 According to this classification, patients with P53 abnormalities have the worst prognosis, while a limited number of patients harboring POLE mutations showed favorable outcomes regardless of differentiation degree and histological type. 27,28 However, the high cost of testing and technical barriers impeded the widespread application of this technology, particularly in underdeveloped medical resource areas and countries. ...

2023 FIGO staging system for endometrial cancer: The evolution of the revolution
  • Citing Article
  • March 2024

Gynecologic Oncology

... Patients with OC require comprehensive information on topics such as sexual health, body image, psychological well-being, social support, work reintegration, and healthcare challenges. Such knowledge is vital for effective self-management and improving quality of life [2][3][4]. Despite the critical importance of accurate and empathetic patient education, individuals with OC frequently encounter barriers in accessing timely, comprehensible, and personalized information. ...

Infrastructural and public health awareness gaps for the diagnosis and treatment of ovarian cancer: A literature review

Archives of Gynecology and Obstetrics

... 2020 yılında O-RADS MRG sözlüğü tanımlanmış [15] ve 2022 yılında adneksal lezyonlarda O-RADS MRG risk sınıflaması geliştirilmiştir (Tablo 3) [11]. US'de belirsiz olarak değerlendirilen lezyonlar O-RADS MRG skoru ile değerlendirildiğinde, asemptomatik hastaların %88,2'sinde gereksiz cerrahinin önüne geçilebileceği gösterilmiştir [16]. Bu sınıflamanın doğru yapılabilmesi için mutlaka, biri transvers en az iki anatomik düzlemde T2 ağırlıklı, transvers düzlemde intravenöz kontrast madde enjeksiyonu öncesi ve sonrası dinamik veya çok fazlı yağ baskılı ...

O-RADS MRI scoring system has the potential to reduce the frequency of avoidable adnexal surgery
  • Citing Article
  • January 2024

European Journal of Obstetrics & Gynecology and Reproductive Biology

... Current clinical guidelines recommend considering secondary CRS in patients with recurrent granulosa cell tumors, always aiming for a complete tumor resection. PFS after secondary CRS has been reported 39-57 months [3,4] and, as mentioned by Iavazzo and Gkegkes [1], the use of adjuvant chemotherapy has not improved survival [3]. We now report an updated PFS of 11 and 59 months, which is in line with other studies summarized by Yasukawa et al. (PFS ranging from 25 months to 19 years) [5]. ...

Effectiveness of adjuvant systemic therapy following complete cytoreductive surgery in patients with recurrent granulosa cell tumours of the ovary

... The quality-of-life aspect will be discussed in the management of HGSOC, and understanding the patient's perspective is indispensable because the disease exerts a profound impact on the physical, psychological, and social dimensions of life. Fear, often described as one of the most dominant emotions, significantly influences patient decision making and their overall treatment experience.79,80 This fear is particularly pronounced in the context of ovarian cancer surgery, which is more extensive compared with surgeries for other malignancies. ...

Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer—Quality of Life Evaluation Research) Prospective, International, Multicentre Study